Cannasouth Limited

CBD

NZCBDE0009S6

Biotechnology & Medical Research

End-of-day quote New Zealand S.E. Other stock markets 04:30:00 25/03/2024 am IST			5-day change	1st Jan Change
0.098 ^NZD	+2.08%		-.--%	-26.32%

29/05	Cannasouth Sets Watershed Meeting for June 7	MT
15/04	Cannasouth Terminates COO	MT

Cannasouth Limited has completed an IPO in the amount of NZD 10 million.

June 18, 2019 at 09:30 am IST

Cannasouth Limited has completed an IPO in the amount of NZD 10 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,000,000 PriceRange: NZD 0.5

Latest news about Cannasouth Limited

Cannasouth Sets Watershed Meeting for June 7	29/05	MT
Cannasouth Terminates COO	15/04	MT
New Zealand Shares Fall on Rate Cut Woes; Cannasouth's CEO Resigns	11/04	MT
Cannasouth CEO Resigns	11/04	MT
Cannasouth Enters Voluntary Administration, CFO Resigns	28/03	MT
Cannasouth Extends Trading Halt, Mulls Restructuring Options	28/03	MT
Cannasouth Shares Placed on Trading Halt	26/03	MT
Cannasouth Limited Reports Revenue Results for the Month of December 2023	23/01	CI
Cannasouth Issues NZ$1.1 Million Convertible Bonds	21/12	MT
Cannasouth Raises Over NZ$2 Million from Sale of Shares, Bonds	12/12	MT
Cannasouth Limited acquired Eqalis Group New Zealand Limited from Eqalis shareholders.	30/23/30	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	29/23/29	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2022	01/23/01	CI
Cannasouth Limited signed a binding term sheet to acquire Eqalis Group New Zealand Limited from Eqalis shareholders for NZD 44.4 million.	19/22/19	CI
Cannasouth Limited Reports Earnings Results for the Half Year Ended June 30, 2022	10/22/10	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	31/22/31	CI
Cannasouth Limited Reports Earnings Results for the Full Year Ended December 31, 2021	01/22/01	CI
Cannasouth Limited completed the acquisition of remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	30/21/30	CI
Cannasouth Limited Announces Unaudited Consolidated Earnings Results for the Six Months Ended 30 June 2021	30/21/30	CI
Cannasouth Limited completed the acquisition of remaining 40% stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin.	02/21/02	CI
Cannasouth Limited signed an agreement to acquire remaining 50% stake in Cannasouth Cultivation Limited from Aaron Craig.	04/21/04	CI
Cannasouth Limited agreed to acquire remaining 40% of stake in Midwest Pharmaceutics NZ Limited from Greenmeadows Health Limited and Mark Balchin for NZD 1 million.	04/21/04	CI
Cannasouth Limited Approves Election of Christine Pears as Non-Executive Independent Director	02/21/02	CI
Cannasouth Limited Auditor Raises 'Going Concern' Doubt	30/21/30	CI
Cannasouth Limited Announces Unaudited Earnings Results for the Year Ended December 31, 2020	25/21/25	CI

Cannasouth Limited is a New Zealand-based biopharmaceutical company focused on medicinal cannabis. The Company is vertically integrated, with business activities ranging from the production and supply of cannabis flower, manufacturing of cannabis-based ingredients and finished dosage products. It also offers an online clinic, and related activities, such as research and development, marketing, and sales. The Company provides a range of imported, Cannasouth-branded medicinal cannabis products. Its subsidiaries include Eqalis Pharmaceuticals Limited, Eqalis Innovation Limited, Cannasouth Bioscience Limited, and Cannasouth Cultivation Limited.

Sector

Biotechnology & Medical Research

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CANNASOUTH LIMITED	-26.32%	2Cr
MODERNA, INC.	+45.88%	5.67TCr
IQVIA HOLDINGS INC.	-7.14%	3.94TCr
LONZA GROUP AG	+39.19%	3.9TCr
CELLTRION, INC.	-6.65%	2.69TCr
ICON PUBLIC LIMITED COMPANY	+12.10%	2.67TCr
ALNYLAM PHARMACEUTICALS, INC.	-21.34%	1.9TCr
BIO-TECHNE CORPORATION	+0.84%	1.23TCr
UNITED THERAPEUTICS CORPORATION	+24.32%	1.23TCr
MEDPACE HOLDINGS, INC.	+26.93%	1.2TCr

Other Biotechnology & Medical Research